|
|
Biotech
|
|
||
Loads of snips$ACAD upgraded to Buy from Neutral at Goldman Sachs. PT $72 from $45 $AMRN negative intellectual property ruling 'serious blow' - Stifel. PT lowered to $8 from $24PT $AMRN PT lowered to $7 from $30 at Leerink $AMRN PT lowered $4 from $27 at Goldman Sachs $AMRN downgraded to Hold from Buy at Jefferies. PT $4 from $30 $RETA Citi removes from Focus List, cuts target to $254 from $328 $PHGE Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin $MYOV & Gedeon Richter Enter into Excl.License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.. $40M upfront to $MYOV Laden $OVID: Soticlestat (OV935) Reduces Seizures in CDKL5 & Dup15q, ARCADE Data; Buy, $20 PT $EYEG Announces Positive Topline Data in Follow-on Dry Eye Pilot Study $BMY $BLUE Announce Submission of Biologics BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA $ARNA initiated with a Buy at Guggenheim. $95 PT $KRTX initiated with a Buy at Guggenheim. $120 PT $AKRO All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in #NASH Phase 2a BALANCED Study $APLS initiated with an Outperform at BMO Capital. $54 PT $KOD initiated with an Outperform at BMO Capital. $74 PT $AZN Lokelma recommended for approval in EU for patients with hyperkalaemia on stable haemodialysis $QGEN Receives FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus #COVID19 $VRNA Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
30995 | Re: Loads of snips | limegoldconvertible68 | 3 | 3/31/2020 7:19:57 AM |
30996 | Re: snips | minxmrphd | 9 | 3/31/2020 7:43:20 AM |